Table 2.
Drug | Allele | FDA | CPIC | ICUR | Willingness-to-pay threshold | Type | Reference++ |
---|---|---|---|---|---|---|---|
Abacavir | HLA-B*5701 | Required | A | $36,700/QALY | $50,000–$100,000/QALY | CE | (60) |
– | – | DT | (64) | ||||
Azathioprine | TPMT | Recommended | A | $49,156/QALY | $50,000/QALY | CE | (BlueCross Blueshield of Western New York, 2018) |
Carbamazepine | HLA-B*1502 1 | Required | A | $85,697/QALY | $50,000/QALY | Not CE | (Stolk et al., 2004) |
$29,750/QALY | $50,000/QALY | CE | (De Lew, 2000) | ||||
Cetuximab | KRAS | Required | – | – | – | Cost saving, same effectiveness | (44) |
Clopidogrel | CYP2C19 2 | Actionable | A | – | – | Dominant | (Jonsson, 2009, 47) |
$4,200/QALY | $100,000/QALY | CE | (Meckley and Neumann, 2010) | ||||
Crizotinib | ALK | Required | – | $136,000/QALY | $200,000/QALY | CE | (Blue Regence, 2019) |
Erlotinib | EGFR | Required | – | ||||
Erlotinib | EGFR | Required | – | $110,658/QALY | $100,000/QALY | Not CE | (86) |
$162,018/QALY | $150,000/QALY | Not CE | (63) | ||||
Panitumumab | KRAS | Required | – | – | – | Cost saving, same effectiveness | (44) |
Phenytoin | HLA-B*1502 1 | Actionable | A | $85,697/QALY | $50,000/QALY | Not CE | (Stolk et al., 2004) |
$29,750/QALY | $50,000/QALY | CE | (De Lew, 2000) | ||||
Trastuzumab | ERBB2 (HER-2) | Required | – | – | – | ||
Vemurafenib | BRAF | Required | – | – | – |
1HLA-B*1502 is regarded medically necessary and thus reimbursed only for patients of Asian ancestry. 2CYP2C19 testing is regarded as medically necessary only for patients with ACS undergoing PCI who are initiating or reinitiating Clopidogrel therapy. CE, Cost-effective; DT, Dominant. ++Identification number of the article ( Supplementary Table 1 ).